Laura M. Cardenoso

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.

Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.

Journal: Antimicrobial agents and chemotherapy

Published: October 21, 2024

Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting.

Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting.

Journal: Vaccines

Published: May 06, 2024

Monkeypox virus genomic accordion strategies.

Monkeypox virus genomic accordion strategies.

Journal: Nature communications

Published: September 06, 2023

Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis.

Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis.

Journal: Frontiers in medicine

Published: May 07, 2023

First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate.

First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate.

Journal: Access microbiology

Published: September 19, 2022

SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort.

SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort.

Journal: Frontiers in medicine

Published: January 15, 2022

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial.

Subcutaneous IL-6 Inhibitor Sarilumab vs. Standard Care in Hospitalized Patients With Moderate-To-Severe COVID-19: An Open Label Randomized Clinical Trial.

Journal: Frontiers in medicine

Published: November 22, 2021

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.

In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO‑WT‑2014-2018 studies in Spain.

Journal: Journal of global antimicrobial resistance

Published: February 08, 2021

First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant.

First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: January 20, 2021

First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant.

First confirmation of importation and transmission in Spain of the newly identified SARS-CoV-2 B.1.1.7 variant.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: January 20, 2021

Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients.

Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients.

Journal: Scientific reports

Published: January 20, 2021

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.

Journal: The Journal of allergy and clinical immunology

Published: May 29, 2020

Showing 1-12 of 25

Last Updated: 09/26/2026